SEC Filings
Erasca Expects Its $947.8 Million Cash Pile To Cover Planned Cancer-Drug Trial Milestones
A July offering strengthened its finances as quarterly research spending rose to $47.2 million from $22.5 million.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
A July offering strengthened its finances as quarterly research spending rose to $47.2 million from $22.5 million.
SEC Filings
The family holding company retained approximately 65.3% of voting power and accepted a 60-day restriction on further sales.
Earnings
Management defined launch speed through prescriptions, prescribers and coverage, while saying sales guidance was premature.
Earnings
Existing supplies cover the planned 21-patient trial, but Lineage still must test its new cell bank and compare production processes.
Insider Trades
Allstate's chief executive retained reported shares worth an estimated $229.8 million at Thursday's close.
Earnings
The company cut its revenue outlook to $91 million–$92 million as disrupted implant accounts and sales-team changes slowed growth.
Insider Trades
The chairman and CEO's proposed sale follows four completed sales that brought in $77.5 million over the past three months.
Earnings
Component shortages slightly constrain the next-quarter outlook, while a separate factory and lab expansion runs through 2030.
Earnings
Specialized AI cloud providers are outside the forecast, and Cisco said its exposure to them is relatively small.
Deals
Management expects $205.5 million in annual cost savings, with the full benefit in place at the beginning of 2028.
Earnings
Chipmaking-equipment sales reached $8.0 billion, and quarterly buybacks and dividends returned $2.42 billion to shareholders.
SEC Filings
Annual costs included a $215 million review voucher that Arrowhead retains while pursuing a broader use for REDEMPLO.